VERVE-102 for hyperlipoproteinemia type ii

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Dec 2023: Trial registered, NCT06164730
  2. 30 Apr 2024: Trial started, NCT06164730

The trials

NCT06164730: A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

State
Under way
Phase
Phase 1
People
85 planned
Started
30 Apr 2024
Primary completion
Oct 2026
Arms
Cohort 1: Single Ascending Dose Escalation, Cohort 2: Single Ascending Dose Escalation, Cohort 3: Single Ascending Dose Escalation, Cohort 4: Single Ascending Dose Escalation, Cohort 5: Single Ascending Dose Escalation, Cohort 6: Single Ascending Dose Escalation, Cohort 7: Single Ascending Dose Escalation, Cohort 8: Single Ascending Dose Escalation, Cohort 9: Single Fixed Dose, Cohort 10: Single Fixed Dose
Results
None posted
  1. 11 Dec 2023: Trial registered
  2. 30 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.